Carlos H Barrios
Overview
Explore the profile of Carlos H Barrios including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
12602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bardia A, Hu X, Dent R, Yonemori K, Barrios C, OShaughnessy J, et al.
N Engl J Med
. 2024 Sep;
391(22):2110-2122.
PMID: 39282896
Background: Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer...
2.
Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro M, et al.
Breast
. 2024 Jun;
76:103756.
PMID: 38896983
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at the last two ABC international consensus conferences (ABC 6 in 2021, virtual, and ABC 7 in 2023,...
3.
Resende H, Arai R, Barrios C, Schwyter F, Teich N, Gomes A, et al.
Ecancermedicalscience
. 2024 May;
18:1698.
PMID: 38774565
Clinical research is the cornerstone of improvements in cancer care. However, it has been conducted predominantly in high-income countries with few clinical trials available in Brazil and other low-and-middle-income countries...
4.
Coles C, Earl H, Anderson B, Barrios C, Bienz M, Bliss J, et al.
Lancet
. 2024 Apr;
403(10439):1895-1950.
PMID: 38636533
No abstract available.
5.
Resende H, Rebelatto T, Werutsky G, Gossling G, Aguiar V, Lopes G, et al.
Ecancermedicalscience
. 2024 Feb;
17:1640.
PMID: 38414936
Background: Epidemiological and clinical cancer research is essential to understanding tumour behaviour and developing new therapies in oncology. However, several countries including Brazil as well as many other regions of...
6.
Al Sukhun S, Temin S, Barrios C, Antone N, Guerra Y, Chavez-MacGregor M, et al.
JCO Glob Oncol
. 2024 Jan;
10:e2300285.
PMID: 38206277
Purpose: To guide clinicians and policymakers in three global resource-constrained settings on treating patients with metastatic breast cancer (MBC) when Maximal setting-guideline recommended treatment is unavailable. Methods: A multidisciplinary, multinational...
7.
Cescon D, Schmid P, Rugo H, Im S, Yusof M, Gallardo C, et al.
J Natl Cancer Inst
. 2023 Dec;
116(5):717-727.
PMID: 38070159
Background: In KEYNOTE-355 (NCT02819518), the addition of pembrolizumab to chemotherapy led to statistically significant improvements in progression-free survival and overall survival in patients with advanced triple-negative breast cancer with tumor...
8.
Schmid P, Turner N, Barrios C, Isakoff S, Kim S, Sablin M, et al.
Clin Cancer Res
. 2023 Dec;
30(4):767-778.
PMID: 38060199
Purpose: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC). Patients And Methods: The...
9.
Moriguchi-Jeckel C, Madke R, Radaelli G, Viana A, Nabinger P, Fernandes B, et al.
Ecancermedicalscience
. 2023 Aug;
17:1582.
PMID: 37533941
Tc-EDDA/HYNIC-TOC is an easily available and cheaper radionuclide that could be used for somatostatin-receptor-based imaging of neuroendocrine tumours (NETs). We aimed to evaluate the diagnostic performance of Tc-EDDA/HYNIC-TOC compared toIn-DTPA-octreotide...
10.
Slamon D, Fasching P, Hurvitz S, Chia S, Crown J, Martin M, et al.
Ther Adv Med Oncol
. 2023 Jun;
15:17588359231178125.
PMID: 37275963
Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer. New...